Inhibiting CSF1R alleviates cerebrovascular white matter disease and cognitive impairment
Inhibiting CSF1R alleviates cerebrovascular white matter disease and cognitive impairment
White matter abnormalities, related to poor cerebral perfusion, are a core feature of small vessel cerebrovascular disease, and critical determinants of vascular cognitive impairment and dementia. Despite this importance there is a lack of treatment options. Proliferation of microglia producing an expanded, reactive population and associated neuroinflammatory alterations have been implicated in the onset and progression of cerebrovascular white matter disease, in patients and in animal models, suggesting that targeting microglial proliferation may exert protection. Colony-stimulating factor-1 receptor (CSF1R) is a key regulator of microglial proliferation. We found that the expression of CSF1R/Csf1r and other markers indicative of increased microglial abundance are significantly elevated in damaged white matter in human cerebrovascular disease and in a clinically relevant mouse model of chronic cerebral hypoperfusion and vascular cognitive impairment. Using the mouse model, we investigated long-term pharmacological CSF1R inhibition, via GW2580, and demonstrated that the expansion of microglial numbers in chronic hypoperfused white matter is prevented. Transcriptomic analysis of hypoperfused white matter tissue showed enrichment of microglial and inflammatory gene sets, including phagocytic genes that were the predominant expression modules modified by CSF1R inhibition. Further, CSF1R inhibition attenuated hypoperfusion-induced white matter pathology and rescued spatial learning impairments and to a lesser extent cognitive flexibility. Overall, this work suggests that inhibition of CSF1R and microglial proliferation mediates protection against chronic cerebrovascular white matter pathology and cognitive deficits. Our study nominates CSF1R as a target for the treatment of vascular cognitive disorders with broader implications for treatment of other chronic white matter diseases.
375-395
Askew, Katharine E.
456faf3f-8c7a-4a23-8a08-95d8cb4141bb
Beverley, Joshua
c5b20aa4-f080-4018-9695-eb3bae5169d1
Sigfridsson, Emma
31fa1b97-e8bf-4de6-af18-4aab935e4ee8
Szymkowiak, Stefan
d72897f6-002d-4651-a943-46429c02204b
Emelianova, Katherine
6cae1974-02ff-4168-a6db-89d1d0c10a89
Dando, Owen
20a98777-28b4-4087-b23e-879ff761ced3
Hardingham, Giles E.
38bd2aed-42b4-4c65-994b-5de17df573df
Duncombe, Jessica
7bb639b7-f106-43b8-a16e-87c9a7e96413
Hennessy, Edel
db710a6a-eaff-414e-9275-c5c79431732c
Koudelka, Juraj
7228628d-34f3-4658-ad4c-3eed72511293
Samarasekera, Neshika
c922f353-83c2-4c56-b2ca-9b1b436fc707
Al-Shahi Salman, Rustam
176e5c16-c13c-42f7-813c-8ba753d5c64f
Smith, Colin
a8cd9f85-aa47-4aa5-bf95-44aa55ebbf84
Tavares, Adriana A.S.
c88a0dc0-8398-4799-944a-d6ecb59f21b7
Gomez-Nicola, Diego
0680aa66-9dee-47cf-a8d3-e39c988f85b5
Kalaria, Raj N.
43c38610-1467-4e6e-8c4b-a82577011d47
McColl, Barry W.
52ac9892-d227-42f9-8c85-3acdeeee11ef
Horsburgh, Karen
f7e20713-b4c3-43f5-97c1-a1538267c346
Askew, Katharine E.
456faf3f-8c7a-4a23-8a08-95d8cb4141bb
Beverley, Joshua
c5b20aa4-f080-4018-9695-eb3bae5169d1
Sigfridsson, Emma
31fa1b97-e8bf-4de6-af18-4aab935e4ee8
Szymkowiak, Stefan
d72897f6-002d-4651-a943-46429c02204b
Emelianova, Katherine
6cae1974-02ff-4168-a6db-89d1d0c10a89
Dando, Owen
20a98777-28b4-4087-b23e-879ff761ced3
Hardingham, Giles E.
38bd2aed-42b4-4c65-994b-5de17df573df
Duncombe, Jessica
7bb639b7-f106-43b8-a16e-87c9a7e96413
Hennessy, Edel
db710a6a-eaff-414e-9275-c5c79431732c
Koudelka, Juraj
7228628d-34f3-4658-ad4c-3eed72511293
Samarasekera, Neshika
c922f353-83c2-4c56-b2ca-9b1b436fc707
Al-Shahi Salman, Rustam
176e5c16-c13c-42f7-813c-8ba753d5c64f
Smith, Colin
a8cd9f85-aa47-4aa5-bf95-44aa55ebbf84
Tavares, Adriana A.S.
c88a0dc0-8398-4799-944a-d6ecb59f21b7
Gomez-Nicola, Diego
0680aa66-9dee-47cf-a8d3-e39c988f85b5
Kalaria, Raj N.
43c38610-1467-4e6e-8c4b-a82577011d47
McColl, Barry W.
52ac9892-d227-42f9-8c85-3acdeeee11ef
Horsburgh, Karen
f7e20713-b4c3-43f5-97c1-a1538267c346
Askew, Katharine E., Beverley, Joshua, Sigfridsson, Emma, Szymkowiak, Stefan, Emelianova, Katherine, Dando, Owen, Hardingham, Giles E., Duncombe, Jessica, Hennessy, Edel, Koudelka, Juraj, Samarasekera, Neshika, Al-Shahi Salman, Rustam, Smith, Colin, Tavares, Adriana A.S., Gomez-Nicola, Diego, Kalaria, Raj N., McColl, Barry W. and Horsburgh, Karen
(2023)
Inhibiting CSF1R alleviates cerebrovascular white matter disease and cognitive impairment.
GLIA, 72 (2), .
(doi:10.1002/glia.24481).
Abstract
White matter abnormalities, related to poor cerebral perfusion, are a core feature of small vessel cerebrovascular disease, and critical determinants of vascular cognitive impairment and dementia. Despite this importance there is a lack of treatment options. Proliferation of microglia producing an expanded, reactive population and associated neuroinflammatory alterations have been implicated in the onset and progression of cerebrovascular white matter disease, in patients and in animal models, suggesting that targeting microglial proliferation may exert protection. Colony-stimulating factor-1 receptor (CSF1R) is a key regulator of microglial proliferation. We found that the expression of CSF1R/Csf1r and other markers indicative of increased microglial abundance are significantly elevated in damaged white matter in human cerebrovascular disease and in a clinically relevant mouse model of chronic cerebral hypoperfusion and vascular cognitive impairment. Using the mouse model, we investigated long-term pharmacological CSF1R inhibition, via GW2580, and demonstrated that the expansion of microglial numbers in chronic hypoperfused white matter is prevented. Transcriptomic analysis of hypoperfused white matter tissue showed enrichment of microglial and inflammatory gene sets, including phagocytic genes that were the predominant expression modules modified by CSF1R inhibition. Further, CSF1R inhibition attenuated hypoperfusion-induced white matter pathology and rescued spatial learning impairments and to a lesser extent cognitive flexibility. Overall, this work suggests that inhibition of CSF1R and microglial proliferation mediates protection against chronic cerebrovascular white matter pathology and cognitive deficits. Our study nominates CSF1R as a target for the treatment of vascular cognitive disorders with broader implications for treatment of other chronic white matter diseases.
Text
Authors final copy Glia 2023
- Accepted Manuscript
More information
Accepted/In Press date: 4 October 2023
e-pub ahead of print date: 1 November 2023
Identifiers
Local EPrints ID: 482720
URI: http://eprints.soton.ac.uk/id/eprint/482720
ISSN: 0894-1491
PURE UUID: 505207a8-6c21-45ce-9c4b-8d08b524d1cd
Catalogue record
Date deposited: 12 Oct 2023 16:31
Last modified: 06 Sep 2025 04:01
Export record
Altmetrics
Contributors
Author:
Katharine E. Askew
Author:
Joshua Beverley
Author:
Emma Sigfridsson
Author:
Stefan Szymkowiak
Author:
Katherine Emelianova
Author:
Owen Dando
Author:
Giles E. Hardingham
Author:
Jessica Duncombe
Author:
Edel Hennessy
Author:
Juraj Koudelka
Author:
Neshika Samarasekera
Author:
Rustam Al-Shahi Salman
Author:
Colin Smith
Author:
Adriana A.S. Tavares
Author:
Raj N. Kalaria
Author:
Barry W. McColl
Author:
Karen Horsburgh
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics